EB-NK-FM (FRalpha/MUC16)

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameEB-NK-FM (FRalpha/MUC16)
Drug Alias NameEB-NK-FM
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionNatural killer cell replacementsMucin-16 modulatorsFolate receptor alpha modulators
TargetsMucin-16Folate receptor alpha
Therapy Area/IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsFallopian Tube NeoplasmsPeritoneal NeoplasmsCarcinoma, Ovarian Epithelial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A